Key statistics
As of last trade, Phathom Pharmaceuticals Inc (PHAT:NSQ) traded at 9.46, 55.98% above the 52 week low of 6.07 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.02 |
---|---|
High | 9.98 |
Low | 8.95 |
Bid | 9.45 |
Offer | 9.47 |
Previous close | 9.45 |
Average volume | 3.05m |
---|---|
Shares outstanding | 68.38m |
Free float | 62.69m |
P/E (TTM) | -- |
Market cap | 646.17m USD |
EPS (TTM) | -5.69 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:03 GMT.
More ▼
- Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
- Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
- Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
- Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
- Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
- Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
- Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
- Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
More ▼